Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin + Pembrolizumab in Advanced RCC and Melanoma
NCT07634380Phase 1Recruiting
- Start
- May 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of sitagliptin in renal cell carcinoma (RCC) and melanoma (2 arms). Primary endpoints: Dose-Limiting Toxicities at 21 days and Overall Response Rate up to 60 months. Started May 2026; status: recruiting.
02
Drugs
sitagliptin
03
Conditions
renal cell carcinoma (RCC)melanoma
Beyond the preview
Go deeper on NCT07634380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07634380.